Amarin Corp Plc (AMRN)

[Dancing in the dark]

infringement via inducement and chronic conditions

since amarin already has vascepa on the market,
could another entity perform a study of EPA for new indication (an indication not currently patented by amarin) with the intent of marketing that new indication themselves WITHOUT inducing providers to infringe with vascepa Rx's?

i think, if not, any new EPA indications go to vascepa.